Delivery Order SPE2DB22D3501-SPE2DB25FWK10
- Not listed
- The Defense Logistics Agency awarded a $48,351.90 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,709.46 on August 12, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $27,728.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). The contract, which is a non-set-aside competitive award with an ultimate completion date of June 3, 2025, represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $4,630.35 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Dupixent 300 mg/2 mL pens totaling $20,114.60 with completion scheduled for July 22, 2025. This competitive, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $42,441.91. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various inflammatory and allergic conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a firm fixed price ceiling value of $15,878.60 and an ultimate completion date of September 18, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $6,612.18. This is a firm fixed price delivery order with no set-aside designation, issued competitively, and is scheduled for completion by September 10, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters is based. This...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWK10Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $16,583.50. This is a firm fixed-price delivery order with no set-aside designation, executed competitively. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 15, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 million through December 2026. Dupixent is a specialty biologic medication used to treat various allergic and inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a wide range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs and other federal health systems. The company's substantial IDC with DLA enables it to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare customers on a global scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.6k | 7/14/25 |